Opthea Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Fred Guerard

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.3yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Fred Guerard (51 yo)

less than a year

Amtszeit

Dr. Frederic Guerard, Pharm. D. M.S. also known as Fred, is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at Lenz Therapeutics, Inc. since 2021.He is a...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Megan Baldwin	Founder	no data	US$1.57m	0.016% $ 80.1k
Judith Robertson	Chief Commercial Officer	2.5yrs	US$856.83k	keine Daten
Karen Adams	VP of Finance & Company Secretary	3.1yrs	US$507.60k	keine Daten
Frederic Guerard	Chief Executive Officer	less than a year	keine Daten	keine Daten
Peter Lang	Chief Financial Officer	less than a year	keine Daten	keine Daten
Sarika Gulhar	Executive Director of Human Resources	1.5yrs	keine Daten	keine Daten
Michael Gerometta	Head of Chemistry	15.6yrs	US$197.04k	keine Daten
Bruno Gagnon	Senior Vice President of Global Clinical Operations	1.8yrs	keine Daten	keine Daten
Kenneth Sall	Chief Medical Officer	less than a year	keine Daten	keine Daten
Fang Li	Senior Vice President of Regulatory Affairs	less than a year	keine Daten	keine Daten
Julie Clark	Senior Vice President of Clinical Development	less than a year	keine Daten	keine Daten
Arshad Khanani	Chief Medical Advisor	less than a year	keine Daten	keine Daten

1.0yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: OPTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Megan Baldwin	Founder	no data	US$1.57m	0.016% $ 80.1k
Jeremy Levin	Chairperson	3.8yrs	US$425.47k	0.0026% $ 12.9k
Jason Slakter	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Quinton Oswald	Independence Non-Executive Director	2.3yrs	US$202.36k	keine Daten
Julia Haller	Independent Non-Executive Director	3.1yrs	US$327.41k	keine Daten
Lawrence Gozlan	Independent Non-Executive Director	4yrs	US$724.31k	0.15% $ 769.7k
Sujal Shah	Non-Executive Director	less than a year	keine Daten	keine Daten
Anshul Thakral	Non-Executive Director	1.1yrs	US$3.16k	keine Daten
Charles Wykoff	Member of Clinical Advisory Board	no data	keine Daten	keine Daten
Susan Orr	Independent Non-Executive Director	2.3yrs	US$206.20k	keine Daten
Andrew Chang	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Tim Jackson	Member of Clinical Advisory Board	no data	keine Daten	keine Daten

2.3yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: OPTDie Vorstandsmitglieder gelten nicht als erfahren ( 2.3 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Opthea Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Opthea Limited Announces Board Appointments

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Recent updates

Price target decreased by 10% to AU$0.79

Opthea Limited Announces Board Appointments

Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million.

Forecast to breakeven in 2027

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Price target increased by 14% to AU$0.90

Consensus revenue estimates decrease by 96%, EPS upgraded

New major risk - Financial position

Consensus revenue estimates increase by 13%

New minor risk - Profitability

Consensus revenue estimates decrease by 14%

Less than half of directors are independent

Consensus EPS estimates fall by 11%

Opthea Limited Announces Board Changes

Consensus revenue estimates fall by 94%

Consensus revenue estimates decrease by 14%, EPS upgraded

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Consensus revenue estimates decrease by 94%

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 94%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 9.0% to AU$1.55

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

Consensus revenue estimates increase by 12%

Consensus EPS estimates upgraded to US$0.25 loss

Consensus EPS estimates fall by 44%

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Consensus revenue estimates increase by 12%

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$173k worth of stock.

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues miss analyst expectations

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Consensus forecasts updated

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Price target decreased to AU$2.95

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Price target decreased to AU$4.24

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302